Vaccine

• 

  Publication Venue For

  • Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older..  39:1339-1348. 2021
  • Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial..  38:6930-6940. 2020
  • Effectiveness of the 10-valent pneumococcal conjugate vaccine against radiographic pneumonia among children in rural Bangladesh: A case-control study..  38:6508-6516. 2020
  • Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants..  38:5355-5363. 2020
  • Efficiency of placental transfer of vaccine-elicited antibodies relative to prenatal Tdap vaccination status..  38:4869-4876. 2020
  • Effectiveness of 'catch-up' human papillomavirus vaccination to prevent cervical neoplasia in immunosuppressed and non-immunosuppressed women..  38:4520-4523. 2020
  • Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination..  38:1678-1689. 2020
  • Immunological mechanisms of inducing HIV immunity in infants..  38:411-415. 2020
  • Engineering immunity for next generation HIV vaccines: The intersection of bioengineering and immunology..  38:187-193. 2020
  • Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis..  37:5535-5543. 2019
  • Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents..  37:5161-5170. 2019
  • An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults..  37:4222-4230. 2019
  • Malaria vaccine trials in pregnant women: An imperative without precedent..  37:763-770. 2019
  • Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women..  36:8054-8061. 2018
  • Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles..  36:6345-6353. 2018
  • Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women..  36:6354-6360. 2018
  • Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines..  36:5600-5608. 2018
  • Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59®-adjuvanted pandemic 2009 H1N1 vaccine..  36:5325-5332. 2018
  • Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants..  36:5020-5029. 2018
  • Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women..  36:4663-4671. 2018
  • Assessing university students' sexual risk behaviors as predictors of human papillomavirus (HPV) vaccine uptake behavior..  36:3629-3634. 2018
  • Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors..  36:3247-3253. 2018
  • Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study..  36:2356-2363. 2018
  • The Advisory Committee on Immunization Practices recommendation regarding the use of live influenza vaccine: A rejoinder..  36:343-344. 2018
  • The effect of antipyretics on immune response and fever following receipt of inactivated influenza vaccine in young children..  35:6664-6671. 2017
  • The effect of timing of influenza vaccination and sample collection on antibody titers and responses in the aged..  35:3700-3708. 2017
  • Report of the WHO technical consultation on the effect of maternal influenza and influenza vaccination on the developing fetus: Montreal, Canada, September 30-October 1, 2015..  35:2279-2287. 2017
  • Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials..  35:1184-1193. 2017
  • DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies..  35:929-937. 2017
  • Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques..  35:639-646. 2017
  • Non-reassuring fetal status: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data..  34:6084-6092. 2016
  • Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV..  34:5886-5894. 2016
  • Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations..  34:5344-5351. 2016
  • Immunization with the Haemophilus ducreyi trimeric autotransporter adhesin DsrA with alum, CpG or imiquimod generates a persistent humoral immune response that recognizes the bacterial surface..  34:1193-1200. 2016
  • Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine..  34:547-554. 2016
  • Use of mobile phones for improving vaccination coverage among children living in rural hard-to-reach areas and urban streets of Bangladesh..  34:276-283. 2016
  • Checkpoint blockade in combination with cancer vaccines..  33:7377-7385. 2015
  • A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice..  33:6596-6603. 2015
  • Initiation & completion rates of hepatitis A vaccination among US pediatric populations born between 2005 and 2009..  33:6871-6877. 2015
  • Maternal benefits of immunization during pregnancy..  33:6436-6440. 2015
  • Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials..  33:6241-6249. 2015
  • Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity..  33:5715-5722. 2015
  • Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine..  33:5425-5431. 2015
  • Serological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers..  33:4141-4145. 2015
  • Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination..  33:3609-3613. 2015
  • Influenza vaccination in children with neurologic or neurodevelopmental disorders..  33:2322-2327. 2015
  • Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials..  33:2347-2353. 2015
  • Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals..  33:1953-1958. 2015
  • Lack of effectiveness of the 23-valent polysaccharide pneumococcal vaccine in reducing all-cause pneumonias among healthy young military recruits: a randomized, double-blind, placebo-controlled trial..  33:1182-1187. 2015
  • Impact of a combined pediatric and adult pneumococcal immunization program on adult pneumonia incidence and mortality in Nicaragua..  33:222-227. 2015
  • Maternal determinants of timely vaccination coverage among infants in rural Bangladesh..  32:5514-5519. 2014
  • Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection..  32:3995-4000. 2014
  • The Haemophilus ducreyi trimeric autotransporter adhesin DsrA protects against an experimental infection in the swine model of chancroid..  32:3752-3758. 2014
  • IFN-γ, but not IL-17A, is required for survival during secondary pulmonary Francisella tularensis Live Vaccine Stain infection..  32:3595-3603. 2014
  • Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children..  31:5706-5712. 2013
  • Human papillomavirus (HPV), HPV-associated oropharyngeal cancer, and HPV vaccine in the United States--do we need a broader vaccine policy?.  31:5500-5505. 2013
  • Research on vaccines during pregnancy: protocol design and assessment of safety..  31:4274-4279. 2013
  • Research on vaccines during pregnancy: reference values for vital signs and laboratory assessments..  31:4264-4273. 2013
  • Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario..  31:3025-3033. 2013
  • Evaluation of vaccine-induced antibody responses: impact of new technologies..  31:2756-2761. 2013
  • A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen..  31:1480-1489. 2013
  • Disparate adjuvant properties among three formulations of "alum"..  31:653-660. 2013
  • Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform..  30:7265-7270. 2012
  • Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009..  30:4240-4248. 2012
  • Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody..  30:4233-4239. 2012
  • Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein..  30:2749-2759. 2012
  • Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study..  30:2047-2050. 2012
  • Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge..  30:1830-1840. 2012
  • SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses..  30:1737-1745. 2012
  • Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques..  30:78-94. 2011
  • Increasing vaccine potency through exosome antigen targeting..  29:9361-9367. 2011
  • Healthy-days time equivalents for outcomes of acute rotavirus infections..  29:8086-8093. 2011
  • Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults..  29:5666-5674. 2011
  • Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges..  29:5611-5622. 2011
  • Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals..  29:3021-3030. 2011
  • The HPV vaccine: are dosing recommendations being followed?.  29:2548-2554. 2011
  • A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects..  29:1948-1958. 2011
  • Employee designation and health care worker support of an influenza vaccine mandate at a large pediatric tertiary care hospital..  29:1762-1769. 2011
  • Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries..  29:878-885. 2011
  • Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age..  28:7865-7872. 2010
  • Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1..  28:6901-6914. 2010
  • Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques..  28:6483-6490. 2010
  • Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally?.  28:4376-4383. 2010
  • Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination..  28:3672-3678. 2010
  • Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus..  28:1702-1708. 2010
  • Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge..  28:299-308. 2009
  • Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals..  27:7141-7148. 2009
  • Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors..  27:5837-5845. 2009
  • Development and use of SIV-based Integrase defective lentiviral vector for immunization..  27:4622-4629. 2009
  • Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates..  27:4709-4717. 2009
  • Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV..  27:3754-3765. 2009
  • Impact of early life exposure to ionizing radiation on influenza vaccine response in an elderly Japanese cohort. 2018